Item 7.01 Regulation FD Disclosure.
Sana Biotechnology, Inc. (the "Company") intends to discuss an updated corporate
presentation (the "Corporate Presentation") at the 41st Annual J.P. Morgan
Healthcare Conference on January 10, 2023. A copy of the Corporate Presentation
is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current
Report") and is incorporated by reference herein.
By furnishing the information in this Item 7.01 of this Current Report,
including Exhibit 99.1, the Company makes no admission as to the materiality of
such information. The information contained herein is intended to be considered
in the context of the Company's filings with the U.S. Securities and Exchange
Commission (the "SEC") and other public announcements that the Company makes, by
press release or otherwise, from time to time. The Company undertakes no duty or
obligation to publicly update or revise the information contained in the
Corporate Presentation, although it may do so from time to time as its
management believes is appropriate. Any such updating may be made through the
filing of other reports or documents with the SEC, through press releases or
through other public disclosure.
In accordance with General Instruction B.2 of Form 8-K, the information
furnished with this Current Report, including Exhibit 99.1, shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended ("Exchange Act"), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any other filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
© Edgar Online, source Glimpses